413
Participants
Start Date
February 17, 2025
Primary Completion Date
January 4, 2029
Study Completion Date
January 5, 2029
BMS-986482
Specified dose on specified days
Nivolumab and rHuPH20
Specified dose on specified days
Nivolumab/relatlimab/rHuPH20
Specified dose on specified days
Bevacizumab
Specified dose on specified days
NOT_YET_RECRUITING
Local Institution - 0017, Ghent
RECRUITING
Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
NOT_YET_RECRUITING
Local Institution - 0038, Athens
NOT_YET_RECRUITING
Local Institution - 0016, Marseille
NOT_YET_RECRUITING
Local Institution - 0036, Rozzano
NOT_YET_RECRUITING
Local Institution - 0037, Milan
NOT_YET_RECRUITING
Local Institution - 0034, Madrid
RECRUITING
Levine Cancer Institute, Charlotte
NOT_YET_RECRUITING
Local Institution - 0035, Pamplona
NOT_YET_RECRUITING
Local Institution - 0008, Aurora
RECRUITING
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
RECRUITING
University of California, Irvine (UCI) Health - UC Irvine Medical Center, Irvine
NOT_YET_RECRUITING
Local Institution - 0012, Villejuif
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
NOT_YET_RECRUITING
Local Institution - 0022, Copenhagen
NOT_YET_RECRUITING
Local Institution - 0039, Thessaloniki
NOT_YET_RECRUITING
Local Institution - 0018, Amsterdam
NOT_YET_RECRUITING
Local Institution - 0028, Rotterdam
NOT_YET_RECRUITING
Local Institution - 0033, Barcelona
NOT_YET_RECRUITING
Local Institution - 0023, Solna
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY